Replies to post #247743 on Biotech Values

[DewDiligence]

Hanmi Pharma* is_running_a_phase-2 NASH trial_with HM15211—which_has_the_same_triple-agonist_MoA as LLY’s Retatrutide:

https://www.clinicaltrials.gov/study/NCT04505436

Trial sites are mostly in the US with a few in South Korea. The listed primary-completion date is May 2025.

Hitting three targets may not be the best way to go, due to the kinds of safety/tolerability issues described in #msg-172222042.

*Private company based in Korea.